These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 3419424)

  • 1. Interactions of liposome-incorporated amphotericin B with kidney epithelial cell cultures.
    Krause HJ; Juliano RL
    Mol Pharmacol; 1988 Sep; 34(3):286-97. PubMed ID: 3419424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of the selective toxicity of amphotericin B incorporated into liposomes.
    Juliano RL; Grant CW; Barber KR; Kalp MA
    Mol Pharmacol; 1987 Jan; 31(1):1-11. PubMed ID: 3807887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions of free and liposomal amphotericin B with renal proximal tubular cells in primary culture.
    Joly V; Saint-Julien L; Carbon C; Yeni P
    J Pharmacol Exp Ther; 1990 Oct; 255(1):17-22. PubMed ID: 2213553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incorporation of amphotericin B (AMB) into liposomes alters AMB-induced acute nephrotoxicity in rabbits.
    Joly V; Dromer F; Barge J; Yeni P; Seta N; Molas G; Carbon C
    J Pharmacol Exp Ther; 1989 Oct; 251(1):311-6. PubMed ID: 2795463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of liposomal amphotericin B formulation.
    Gulati M; Bajad S; Singh S; Ferdous AJ; Singh M
    J Microencapsul; 1998; 15(2):137-51. PubMed ID: 9532520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin - beta complexed with different chemically modified beta - cyclodextrins.
    Chakraborty KK; Naik SR
    J Pharm Pharm Sci; 2003; 6(2):231-7. PubMed ID: 12935435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro studies on liposomal formulations of amphotericin B and its derivative, N-methyl-N-D-fructosyl amphotericin B methyl ester (MFAME).
    Cybulska B; Kupczyk K; Szlinder-Richert J; Borowski E
    Acta Biochim Pol; 2002; 49(1):67-75. PubMed ID: 12136958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective toxicity and enhanced therapeutic index of liposomal polyene antibiotics in systemic fungal infections.
    Juliano RL; Lopez-Berestein G; Hopfer R; Mehta R; Mehta K; Mills K
    Ann N Y Acad Sci; 1985; 446():390-402. PubMed ID: 3860162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymerized phospholipid vesicles containing amphotericin B: evaluation of toxic and antifungal activities in vitro.
    Mehta R; Hsu MJ; Juliano RL; Krause HJ; Regen SL
    J Pharm Sci; 1986 Jun; 75(6):579-81. PubMed ID: 3525815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B.
    Smith PJ; Olson JA; Constable D; Schwartz J; Proffitt RT; Adler-Moore JP
    J Antimicrob Chemother; 2007 May; 59(5):941-51. PubMed ID: 17400589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyene antibiotics: relative degrees of in vitro cytotoxicity and potential effects on tubule phospholipid and ceramide content.
    Zager RA
    Am J Kidney Dis; 2000 Aug; 36(2):238-49. PubMed ID: 10922301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemolytic and antifungal activity of liposome-entrapped amphotericin B prepared by the precipitation method.
    Kim JC; Lee EO; Kim JY; Bae SK; Choi TB; Kim JD
    Pharm Dev Technol; 1997 Aug; 2(3):275-84. PubMed ID: 9552455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
    Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
    J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice.
    Rust DM; Jameson G
    Oncol Nurs Forum; 1998; 25(1):35-48. PubMed ID: 9460772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of the toxicity of a new lipid complex formulation of amphotericin B.
    Larabi M; Pages N; Pons F; Appel M; Gulik A; Schlatter J; Bouvet S; Barratt G
    J Antimicrob Chemother; 2004 Jan; 53(1):81-8. PubMed ID: 14657087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Water-soluble amphotericin B-polyvinylpyrrolidone complexes with maintained antifungal activity against Candida spp. and Aspergillus spp. and reduced haemolytic and cytotoxic effects.
    Charvalos E; Tzatzarakis MN; Van Bambeke F; Tulkens PM; Tsatsakis AM; Tzanakakis GN; Mingeot-Leclercq MP
    J Antimicrob Chemother; 2006 Feb; 57(2):236-44. PubMed ID: 16361329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aerosolized liposomal amphotericin B: prediction of lung deposition, in vitro uptake and cytotoxicity.
    Fauvel M; Farrugia C; Tsapis N; Gueutin C; Cabaret O; Bories C; Bretagne S; Barratt G
    Int J Pharm; 2012 Oct; 436(1-2):106-10. PubMed ID: 22814222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal amphotericin B and amphotericin B-deoxycholate show different immunoregulatory effects on human peripheral blood mononuclear cells.
    Reyes E; Cardona J; Prieto A; Bernstein ED; Rodríguez-Zapata M; Pontes MJ; Alvarez-Mon M
    J Infect Dis; 2000 Jun; 181(6):2003-10. PubMed ID: 10837182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the leishmanicidal activity of fungizone, liposomal AmB and amphotericin B incorporated into egg lecithin-bile salt mixed micelles.
    Ramos H; Brajtburg J; Marquez V; Cohen BE
    Drugs Exp Clin Res; 1995; 21(6):211-6. PubMed ID: 8907695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High purity amphotericin B.
    Cleary JD; Chapman SW; Swiatlo E; Kramer R
    J Antimicrob Chemother; 2007 Dec; 60(6):1331-40. PubMed ID: 17921178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.